Cavion, Inc.
  • Founded: 2016
  • CEO: Andrew Krouse
  • Size of Facility: 2000 sq ft
  • Company Size: 15
  • Funding Source: Grants (e.g. SBIR, CRCF, CIT), Investor Funded, Venture Captital/Private Equity
  • Development Stage: Phase 1-2 Clinical Trials

Cavion, Inc. is a privately-held clinical-stage biotech company focused on developing first-in-class T-type calcium channel modulators to restore the brain’s natural rhythms in neurological diseases such as essential tremor, movement disorders and rare epilepsies.